1. Q waves are the strongest electrocardiographic variable associated with primary prophylactic implantable cardioverter-defibrillator benefit:a prospective multicentre study
- Author
-
Pelli, A. (Ari), Junttila, M. J. (M. Juhani), Kenttä, T. V. (Tuomas, V), Schlogl, S. (Simon), Zabel, M. (Markus), Malik, M. (Marek), Reichlin, T. (Tobias), Willems, R. (Rik), Vos, M. A. (Marc A.), Harden, M. (Markus), Friede, T. (Tim), Sticherling, C. (Christian), Huikuri, H. V. (Heikki, V), and the EU-CERT-ICD Study Investigators
- Subjects
QT interval ,Primary prevention ,Heart failure ,Benefit ,Mortality ,Q wave ,Appropriate shock ,Implantable cardioverter-defibrillator ,Electrocardiogram - Abstract
Aim: The association of standard 12-lead electrocardiogram (ECG) markers with benefits of the primary prophylactic implantable cardioverter-defibrillator (ICD) has not been determined in the contemporary era. We analysed traditional and novel ECG variables in a large prospective, controlled primary prophylactic ICD population to assess the predictive value of ECG in terms of ICD benefit. Methods and results: Electrocardiograms from 1477 ICD patients and 700 control patients (EU-CERT-ICD; non-randomized, controlled, prospective multicentre study; ClinicalTrials.gov Identifier: NCT02064192), who met ICD implantation criteria but did not receive the device, were analysed. The primary outcome was all-cause mortality. In ICD patients, the co-primary outcome of first appropriate shock was used. Mean follow-up time was 2.4 ± 1.1 years to death and 2.3 ± 1.2 years to the first appropriate shock. Pathological Q waves were associated with decreased mortality in ICD patients [hazard ratio (HR) 0.54, 95% confidence interval (CI) 0.35–0.84; P
- Published
- 2022